New York Medical College

New York Medical College, doing business as Administration Building, is a tax-exempt private medical college subsidiary of Touro University located in Valhalla, New York, that operates as a prime recipient on federal grants and a prime contractor on federal education and medical research contracts, with no characteristic set-aside designations across its footprint. The institution primarily pursues full-and-open federal work in medical education, biomedical research, and clinical trial support, competing on institutional capability and peer-review merit rather than SBA certifications.

The college's federal portfolio centers on three capability streams: graduate medical education supported by the Department of the Navy Bureau of Medicine and Surgery through tuition and fees delivery orders; investigator-initiated biomedical research grants from the National Institutes of Health across multiple institutes; and clinical trial execution as a site principal investigator or sub-awardee on multi-center studies. Representative prime contract work includes seven delivery orders (2022–2026) issued by the Navy's Bureau of Medicine and Surgery for tuition and fees support, ranging from $32,413 to $141,535 in ceiling value per order, all firm fixed-price under a single-award Basic Ordering Agreement with a ceiling of $0 (indefinite delivery vehicle) running through January 2032. On the research side, NYMC holds prime grant awards from NINDS for preclinical epilepsy research ($162,400 project grant awarded May 2026, completion April 2028), from NIAID for mucosal vaccine development against Pseudomonas aeruginosa ($261,846 project grant, July 2025, with University of California Davis as named sub-awardee), from NHLBI for cardiovascular physiology and metabolic disease mechanistic studies, and from the National Cancer Institute and Defense Health Agency for oncology and immunotherapy trials. A $2.6 million FDA contract awarded September 2022 characterizes COVID-19 vaccine-associated myocarditis and informs surveillance protocols, running through September 2027.

Customer concentration anchors heavily on two agencies accounting for approximately 55% of recent awards by count. The Department of the Navy Bureau of Medicine and Surgery commands 67 awards with $5.2 million combined potential value, driven by recurring delivery orders under the standing BOA for medical education support. The National Institutes of Health (across all constituent institutes) accounts for 110 awards by aggregate count; within NIH, the National Heart, Lung, and Blood Institute (24 awards), the National Institute of Allergy and Infectious Diseases (19 awards), and the National Institute of Neurological Disorders and Stroke together dominate the grant portfolio. NASA's Shared Services Center places 4 awards with $1.5 million potential value. The distribution signals that NYMC's primary federal revenue stream derives from Navy-supported graduate medical education tuition and from peer-reviewed research grants across the NIH institutes, with modest exposure to federal research infrastructure funding.

Vehicle position is concentrated on Navy education contracts. The top parent vehicle, Basic Ordering Agreement N0018912GZ008, carries 39 task orders valued at $2.9 million combined; Indefinite Delivery Contract N0014098G2497 carries 30 task orders at $2.3 million combined. These vehicles serve as the contracting mechanism for Navy medical education procurement, with delivery orders issued episodically to cover tuition, fees, and related student support costs. NYMC holds no seats on government-wide GWACs, multiple-award schedules, or agency IDIQs outside the Navy's education BOAs.

Activity trajectory shows modest growth with some volatility: 12 awards in FY2022, 11 in FY2023, 17 in FY2024, 15 in FY2025, and 5 recorded through May 2026. Sixteen awards (combined potential value $2.6 million) reach ultimate completion within the next twenty-four months and face recompete exposure. The Navy tuition delivery orders, which run on annual or semi-annual cycles under the standing BOA, generate recurring recompete opportunity as existing orders reach completion and the Navy issues successor orders.

Service Contract Inventory reporting, which captures federal service contracts above the $150,000 threshold, shows negligible SCI activity: zero dollars invoiced across FY2022–FY2024 on NYMC's three prime SCI records, with fewer than 1 FTE per fiscal year. This narrow SCI footprint reflects that NYMC's federal work is predominantly education (tuition pass-through), grants (research), and clinical trial execution — categories outside the SCI reporting scope — rather than billable federal services contracts.

As a prime on 91% of recent awards, NYMC builds most delivery in-house through its own faculty and research staff. Sub-award activity (9% of awards) positions the institution as a site investigator or sub-recipient on multi-center NIH-funded trials led by Johns Hopkins University, Columbia University, University of California Los Angeles, Northwestern University, Yale University, Rutgers University, Cincinnati University, and others. Named sub-grant work includes participation in stroke trials networks (Columbia University prime), COVID-19 severity prediction consortia (Rutgers prime), tick-borne disease biomarker development (Colorado State University prime), and kidney transplant outcomes research (Weill Cornell prime). NYMC contributes clinical expertise, patient recruitment, data collection, and biostatistical analysis on these studies rather than serving as project leadership.

Corporate structure shows NYMC as a child entity of Touro University, a larger private non-profit education system. The relationship is administrative; federal awards are issued to New York Medical College as the performing institution, and Touro does not appear as a direct federal contractor or grantee in the source.